straga/iStock via Getty Images European natural gas futures fell as much as 20% Wednesday after the U.S. and Iran agreed to a two-week ceasefire that could temporarily reopen the Strait of Hormuz and ease strained global energy markets. Dutch front-month futures, Europe's gas benchmark, recently traded 17% lower at € 44.13/MWh, the lowest since March 2—the first trading day after the start of U.S....
straga/iStock via Getty Images European natural gas futures fell as much as 20% Wednesday after the U.S. and Iran agreed to a two-week ceasefire that could temporarily reopen the Strait of Hormuz and ease strained global energy markets. Dutch front-month futures, Europe's gas benchmark, recently traded 17% lower at € 44.13/MWh, the lowest since March 2—the first trading day after the start of U.S. and Israeli strikes on Iran—which saw prices climb to as high as €74/MWh. But little has changed fundamentally so far, Wood Mackenzie's Europe gas and LNG director Tom Marzec-Manser told Bloomberg. "Aside from trapped laden LNG carriers inside the Gulf—which may still struggle to depart if the Strait is not truly open—it is the restart of Qatar's Ras Laffan that really matters," he said, referring to the massive liquefied natural gas hub that was severely damaged by Iranian attacks. Wood Mackenzie has warned if QatarEnergy begins restarting Ras Laffan in early May, it would take until the end of August for its 12 operable trains to return to full service, and Qatar has said repairs on two others could take as long as five years. ETFs: ( UNG ), ( BOIL ), ( KOLD ), ( UNL ), ( FCG ) More on U.S. natural gas Commodities: Oil Climbs On Trump Escalation Threat Weather Drops U.S. January Oil Production Commodities: Iran Hits UAE And Bahrain Aluminum Plants
Royal Concert Hall, Glasgow There is something eternally teenage about the trailblazing rocker, who can still deliver at her glam-era best – but her rambling reminiscences are a bit Alan Partridge Suzi Quatro has a confession. At 75, age has taken its toll, she tells the Glasgow crowd. She has lost an inch in height and is now 5ft 1in. “But,” she grins, “I can still scream just as loud.” Proof com...
Royal Concert Hall, Glasgow There is something eternally teenage about the trailblazing rocker, who can still deliver at her glam-era best – but her rambling reminiscences are a bit Alan Partridge Suzi Quatro has a confession. At 75, age has taken its toll, she tells the Glasgow crowd. She has lost an inch in height and is now 5ft 1in. “But,” she grins, “I can still scream just as loud.” Proof comes during 48 Crash. It is a thrilling noise, the Suzi Q scream, a holler of swallow-the-world desire and a defining sound of the glam era. She has been screaming like that since she was a kid playing dance halls around Detroit. There is something eternally teenage about her, an innocent in black leather, so that even when she covers Neil Young’s Rockin’ in the Free World, towards the end of the first of two sets, she drains the song of anger and floods it with galvanising sincerity. While the opening hour is entertaining and well paced, the second, longer set is a mess of lesser material, tedious solos and drawn-out introductions of her eight-piece band. Worst is the stretch in which Quatro runs through her career with the aid of pictures: “Fifteen years on BBC Radio 2. I was up for broadcaster of the year at the Sony Radio awards.” Ever wondered what it would be like if Alan Partridge delivered a PowerPoint in the middle of a rock gig? Not great. Continue reading...
ilbusca/iStock Unreleased via Getty Images Levi Strauss ( LEVI ) rallied in early trading on Wednesday after impressing analysts and investors with its first-quarter earnings report. Higher denim prices and strong direct-to-consumer were positive factors during the quarter. Needham analyst Tom Nikic said Levi Strauss ( LEVI ) started the year with a solid beat-and-raise, demonstrating continued mo...
ilbusca/iStock Unreleased via Getty Images Levi Strauss ( LEVI ) rallied in early trading on Wednesday after impressing analysts and investors with its first-quarter earnings report. Higher denim prices and strong direct-to-consumer were positive factors during the quarter. Needham analyst Tom Nikic said Levi Strauss ( LEVI ) started the year with a solid beat-and-raise, demonstrating continued momentum. The firm was encouraged by the fact that the apparel giant continues to perform well in their key areas of focus. "We remain bullish on LEVI shares, as we believe they are benefiting from solid execution of internal initiatives and a denim trend that is working in their favor," he noted. Needham has a Buy rating on LEVI and a price target of $28. BTIG was also impressed with the report. Analyst Robert Drbul said the quarter continued to highlight the traction behind Levi Strauss' ( LEVI ) denim lifestyle and premiumization strategy. He observed that women’s revenue increased 13% and tops grew 13%, with tops accounting for roughly one-third of total company growth, underscoring continued expansion of the addressable market beyond core denim. "Growth was balanced between unit volume and AUR, supported by innovation, mix, and pricing actions," highlighted Drbul. BTIG has a Buy rating on LEVI and a price target of $27. Barclays also weighed in favorably. "The company saw strength across all regions and channels. "We remain Overweight rated as the fundamentals remain strong and encouraging with further proof points that its long-term strategic initiatives are working," updated analyst Adrienne Yih. Wells Fargo kept Levi Strauss ( LEVI ) slotted as a top pick after the earnings release. Analyst Ike Boruchow said the company's top-line momentum is sustainable and the margin trajectory is shifting for the better. The firm kept an Overweight rating on LEVI and a price target of $25. Shares of Levi Strauss ( LEVI ) rallied 9.8% in premarket trading to $21.65 vs. the 52-week r...
Grandbrothers/iStock Editorial via Getty Images Mesoblast ( MESO ) added ~6% in the premarket on Wednesday after the FDA cleared its Investigational New Drug application that sought approval to conduct a study to test its cell therapy, Ryoncil, in Duchenne muscular dystrophy, a rare muscle disorder. In 2024, the FDA approved Ryoncil as the only mesenchymal stromal cell therapy available in the U.S...
Grandbrothers/iStock Editorial via Getty Images Mesoblast ( MESO ) added ~6% in the premarket on Wednesday after the FDA cleared its Investigational New Drug application that sought approval to conduct a study to test its cell therapy, Ryoncil, in Duchenne muscular dystrophy, a rare muscle disorder. In 2024, the FDA approved Ryoncil as the only mesenchymal stromal cell therapy available in the U.S. for children aged two months and older with steroid-refractory acute graft-versus-host disease. Australian biotech said that the IND clearance allows it to directly conduct a registrational trial for Ryoncil in DMD, which affects about 15K American children. The 76-patient trial for children aged 5 to 9 years is designed to test Ryoncil alongside the standard of care for DMD, with its primary endpoint being time-to-stand at nine months, an established FDA standard for approval of Duchenne therapies. “Our experience with Ryoncil suggests that we may have a unique approach to help with this devastating disease in children,” CEO Silviu Itescu remarked. More on Mesoblast Mesoblast Limited (MESO) Q2 2026 Earnings Call Transcript Mesoblast: Real-World Data Validates The Bull Case For Ryoncil Mesoblast drops after Ryoncil sales data for March quarter Mesoblast rises as Ryoncil sales climb 60% in December quarter Seeking Alpha’s Quant Rating on Mesoblast
SoftBank Corp. , a unit of Japanese conglomerate SoftBank Group Corp. , is preparing to sell its first euro-denominated bond as founder Masayoshi Son makes a big push into artificial intelligence. The unit, which listed in 2018 as the mobile arm of SoftBank Group, has mandated a group of banks to arrange investor calls in Asia and Europe starting Wednesday, according to a person familiar with the ...
SoftBank Corp. , a unit of Japanese conglomerate SoftBank Group Corp. , is preparing to sell its first euro-denominated bond as founder Masayoshi Son makes a big push into artificial intelligence. The unit, which listed in 2018 as the mobile arm of SoftBank Group, has mandated a group of banks to arrange investor calls in Asia and Europe starting Wednesday, according to a person familiar with the matter. The potential sale is for benchmark-sized, fixed-rate senior unsecured euro tranches with long six- and 10-year maturities, they said. SoftBank Corp., which also includes financial services and AI, sold its first US high-grade bond last year. The $1 billion offering of five- and 10-year debt drew demand more than seven times the size of the transaction and priced inside initial guidance. Parent company SoftBank Group is currently exploring raising as much as $40 billion in the loan market, mostly to help finance its investment in US tech giant OpenAI. That would be its largest-ever dollar-denominated borrowing, and comes as Son tries to position his company as a linchpin in the global AI boom. Read: SoftBank Seeks Record Loan of Up to $40 Billion for OpenAI Stake The conglomerate’s aggressive push into AI has drawn some scrutiny from ratings firms. S&P Global Ratings recently revised its outlook on SoftBank Group to negative, citing risks related to its growing exposure to OpenAI and broader funding needs. Europe’s primary market has seen a rush of borrowers today after the US and Iran agreed to a two-week ceasefire, sparking a wave of optimism in financial markets and easing measures of credit risk. At least 11 deals are slated to price, the most since March 16, according to data compiled by Bloomberg. Read: Bond Sales Are Back in Force as Iran Ceasefire Eases Credit Risk JPMorgan Chase & Co., BNP Paribas SA, Citigroup Inc., and Mizuho are organizing SoftBank Corp.’s investor calls. The offering, which will depend on market conditions, is expected to be rated BBB b...
FactSet Research Systems ( FDS ) announced on Wednesday the appointment of Joshua Warren as CFO, effective April 13. Warren will succeed Helen Shan. The Norwalk, Connecticut-based company was trading 0.46% higher at $228.79 before the market open. Most recently, Warren served as CFO of Envestnet. He has served as global head of business strategy for iShares and Index Investments at BlackRock ( BLK...
FactSet Research Systems ( FDS ) announced on Wednesday the appointment of Joshua Warren as CFO, effective April 13. Warren will succeed Helen Shan. The Norwalk, Connecticut-based company was trading 0.46% higher at $228.79 before the market open. Most recently, Warren served as CFO of Envestnet. He has served as global head of business strategy for iShares and Index Investments at BlackRock ( BLK ). Additionally, he has held the role of managing director in BlackRock's corporate strategy and development team. FactSet said Shan's departure is not the result of any disagreement regarding the company's accounting practices, financial statements, or financial condition, or any of the company's related disclosures. More on FactSet Research Systems FactSet Research Systems: Fundamental And Valuation Facts Should Set Its Rebound FactSet Research Systems: Valuation Multiple Is Too Cheap FactSet Research Systems Inc. (FDS) Q2 2026 Earnings Call Transcript FactSet expects $130M-$160M ASV growth in fiscal 2026 while raising adjusted EPS outlook to $17.25-$17.75 FactSet Research Systems Non-GAAP EPS of $4.46 beats by $0.08, revenue of $611M beats by $6.05M